Total submissions: 4
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Institute for Genomic Medicine |
RCV006253739 | SCV007105122 | tier i - strong | Pilocytic astrocytoma | 2024-10-04 | criteria provided, single submitter | clinical testing | Variant has Tier I (strong) clinical significance as a diagnostic inclusion criterion in pilocytic astrocytoma, based on the following evidence: 1) Documented in one or more cancer databases (e.g., St. Jude Pecan, COSMIC, CIViC, OncoKB). 2) Appears in one or more well-established professional guidelines (e.g., World Health Organization [WHO]; National Comprehensive Cancer Network [NCCN]) as providing diagnostic, prognostic, or therapeutic information. 3) Information in the literature supports potential biologic effect of variant (PMID: 28783719). 4) Diagnostic for a specific tumor type/classification according to professional guidelines (Evidence Level A; PMIDs: 23583981, 25785246, 28912153, 32289278). |
| Laboratory for Molecular Medicine, |
RCV000037931 | SCV000061596 | likely pathogenic | Non-small cell lung carcinoma | 2010-05-13 | criteria provided, single submitter | clinical testing | |
| Key Laboratory of Carcinogenesis and Cancer Invasion, |
RCV000443573 | SCV004042819 | likely pathogenic | Lung adenocarcinoma | no assertion criteria provided | clinical testing | ||
| Laboratory of Virology, |
RCV002291550 | SCV002584891 | uncertain significance | Prostate cancer, hereditary, 1 | 2022-07-29 | no assertion criteria provided | clinical testing |